CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic...
Phase 1
Boston, Massachusetts, United States and 3 other locations
over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic...
Phase 2
Boston, Massachusetts, United States and 2 other locations
new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic...
Phase 2
Boston, Massachusetts, United States and 8 other locations
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Boston, Massachusetts, United States and 40 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 2
Boston, Massachusetts, United States of America and 47 other locations
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of t...
Phase 2
Boston, Massachusetts, United States and 7 other locations
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic le...
Phase 1, Phase 2
Boston, Massachusetts, United States and 11 other locations
new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic...
Phase 1, Phase 2
Boston, Massachusetts, United States and 1 other location
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic...
Phase 2
Boston, Massachusetts, United States and 3 other locations
with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....
Phase 1
Boston, Massachusetts, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal